CATHETER RELATED BLOOD STREAM INFECTION MARKET ANALYSIS

Market Challenges And Opportunities

Global Catheter Related Blood Stream Infection Market – Dynamics

Furthermore, WHO study indicates that most of the countries lack in the surveillance systems for infections related to health care and these reasons often result in struggle with the complexity and lack of standardized criteria for diagnosing the infections. Serious effects are associated with inaccurate diagnosis, results complication or lead to increase in mortality and morbidity. Due to which it is necessary to diagnose catheter related bloodstream infection accurately.

Likewise, the market players are conducting research and development activities for the innovation of better products for the prevention of catheter related blood stream infection. This is expected to increase the growth of the global catheter related bloodstream infection market over the forecast period. For instance, on August 4, 2021, Citius Pharmaceuticals, an  biopharmaceutical company which focused on development and commercialization of products based on critical care. Company announced that, Mino-Lok it is an antibiotic lock solution, which is used for treatment of patients with catheter related bloodstream infection. As per phase 2b trial results Mino lok demonstrated 100 % efficacy rate. And multicenter phase 3 clinical trial of Mino-Lok is currently underway. Mini-Lok by Citius pharmaceuticals has potential to be the first and only Food and Drug Administration (FDA) approved product to be used for infected CVCs and the company plans to file a new drug application (NDA) in 2022.

Due to the rising cases in health care associated infections in the U.S., the government provides reimbursement policy to the patients. For instance, as per programs in centers for Medicare and Medicaid services (CMS), the HAC Reduction Program provide services for catheter related bloodstream infection. This program encourage hospitals to provide safety assurance to infected patients. The Medicare provided through this program is US$ 9,504 Mn.